TWD 70.2
(-2.9%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 18.57 Million TWD | 1.38% |
2022 | 34.01 Million TWD | 231.53% |
2021 | 10.25 Million TWD | 156.88% |
2020 | -18.03 Million TWD | -259.84% |
2019 | 11.28 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 22.2 Million TWD | 23.08% |
2024 Q1 | 18.04 Million TWD | 106.73% |
2023 Q4 | 8.72 Million TWD | 47.38% |
2023 FY | 34.48 Million TWD | 1.38% |
2023 Q3 | 5.92 Million TWD | -43.69% |
2023 Q2 | 10.51 Million TWD | 12.87% |
2023 Q1 | 9.31 Million TWD | 110.79% |
2022 FY | 34.01 Million TWD | 231.53% |
2022 Q4 | 4.42 Million TWD | 0.0% |
2021 FY | 10.25 Million TWD | 156.88% |
2020 FY | -18.03 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
BIONET Corp. | 84.69 Million TWD | 78.067% |
DIVA Laboratories, Ltd. | 92.15 Million TWD | 79.842% |
Welgene Biotech Co.,Ltd. | -4.25 Million TWD | 536.159% |
Puriblood Medical Co., Ltd. | -50.4 Million TWD | 136.855% |
TFBS Bioscience Inc. | -4.45 Million TWD | 517.157% |